Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 8931 results

  1. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation

    In development Reference number: GID-IPG10216 Expected publication date: TBC

  2. Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma

    In development Reference number: GID-HTG10153 Expected publication date: TBC

  3. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

  4. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

  5. Surgical mesh for treatment of primary ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date:  03 February 2027

  6. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date: TBC

  7. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Highly specialised technology. Comments close 24 February 2026.

  8. Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

    Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis

  9. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

  10. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  11. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

  12. Digital ulcers: sildenafil (ESUOM42)

    Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

  13. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  14. Symptoms of peripheral arterial disease: ramipril (ESUOM45)

    Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

  15. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making